January 2025

YANTAI, China, Jan. 8, 2025 /PRNewswire/ — On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term follow-up results of a phase 1b/2 clinical trial on Disitamab Vedotin (DV) (developed by Remegen Co., Ltd) combined with Toripalima

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: